{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:05:35Z","timestamp":1789452335251,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pemphigus is an autoimmune bullous disease. PNP\/PAMS represents a rare subtype of autoimmune bullous disease, and typically associated with an underlying neoplasm, particularly lymphoproliferative disorders. Current management of PNP primarily involves glucocorticoids, immunosuppressants, and rituximab. This article reports a 67-year-old male who presented with generalized erythema, blisters, and oral erosions with pain for one month. Initially diagnosed with pemphigus, he received methylprednisolone treatment, which led to slight improvement in skin lesions but minimal resolution of oral ulcers. Based on the available clinical, histopathological, immunofluorescence, and serological findings, the patient was initially diagnosed with pemphigus vulgaris in the setting of CLL. However, the refractory oral mucositis, dual positivity for Dsg1 and Dsg3, and the underlying B-cell malignancy raised the concern for paraneoplastic pemphigus (PNP). Given that PNP-specific tests\u2014including anti-plakin antibodies, indirect immunofluorescence on rat bladder, and immunoblotting\u2014were not performed, a definitive diagnosis of PNP could not be established. Therefore, the condition was managed as \u201csuspected CLL-associated PNP\u201d Following the initiation of zanubrutinib in combination with ongoing corticosteroid therapy and CLL treatment, significant improvement of oral erosions was observed. In this case, the clinical improvement may be potentially related to zanubrutinib, but the concurrent corticosteroid therapy and the control of CLL likely contributed as well. If zanubrutinib did play a role, the mechanism might involve enhanced disease control or immune modulation. However, the current evidence is insufficient to draw a firm conclusion, and its true efficacy needs to be evaluated in further studies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1876086","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:36:40Z","timestamp":1789450600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical improvement of pemphigus-like mucocutaneous disease in a patient with CLL following initiation of zanubrutinib: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Tianyu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Kunming Medical University","place":["Yunnan, Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbin","family":"Lu","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Kunming Medical University","place":["Yunnan, Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Kunming Medical University","place":["Yunnan, Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjie","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Kunming Medical University","place":["Yunnan, Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.31729\/jnma.7594","article-title":"Delayed diagnosis of pemphigus vulgaris initially presenting as an oral ulcer: a case report","volume":"60","author":"Lamichhane","year":"2022","journal-title":"Jnma J Nepal Med Assoc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363032","article-title":"State-of-the-art diagnosis of autoimmune blistering diseases","volume":"15","author":"van Beek","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3892\/etm.2021.10770","article-title":"Comprehensive review on the pathophysiology, clinical variants and management of pemphigus (review)","volume":"22","author":"Costan","year":"2021","journal-title":"Exp Ther Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaad.2023.08.084","article-title":"Paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome: part II. Diagnosis and management","volume":"91","author":"Huang","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2023.08.020","article-title":"Paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome: part I. Clinical overview and pathophysiology","volume":"91","author":"Anderson","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3641474","article-title":"Paraneoplastic pemphigus: a striking complication of undiagnosed lymphoma","volume":"2022","author":"Adnani","year":"2022","journal-title":"Case Rep Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1132535","article-title":"A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL","volume":"10","author":"Chen","year":"2023","journal-title":"Front Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14023","article-title":"Paraneoplastic pemphigus associated with post-transplant lymphoproliferative disorder after small bowel transplantation","volume":"25","author":"Fidder","year":"2021","journal-title":"Pediatr Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14684","article-title":"Paraneoplastic pemphigus misdiagnosed as juvenile dermatomyositis: a case report","volume":"26","author":"Gao","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15144","article-title":"Therapy of paraneoplastic pemphigus with rituximab: a case report","volume":"34","author":"Zhang","year":"2021","journal-title":"Dermatol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ph18111674","article-title":"Therapeutic impact of zanubrutinib in chronic lymphocytic leukemia: evidence from a systematic review and single-arm meta-analysis","volume":"18","author":"Alatawi","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02238-7","article-title":"Zanubrutinib monotherapy for na\u00efve and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: a pooled analysis of three studies","volume":"39","author":"Xu","year":"2022","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-03925-1","article-title":"Zanubrutinib in japanese treatment-naive and relapsed\/refractory patients with waldenstr\u00f6m macroglobulinemia and CLL\/SLL","volume":"121","author":"Izutsu","year":"2025","journal-title":"Int J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01592-0","article-title":"Bruton\u2019s tyrosine kinase inhibition as an emerging therapy in systemic autoimmune disease","volume":"81","author":"Neys","year":"2021","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177747","article-title":"Next generation bruton\u2019s tyrosine kinase inhibitors - characterization of in vitro potency and selectivity","volume":"1002","author":"Pulz","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103532","article-title":"Inhibitors of bruton\u2019s tyrosine kinase as emerging therapeutic strategy in autoimmune diseases","volume":"23","author":"De Bondt","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015596","article-title":"Outcomes after transition from ibrutinib to zanubrutinib in patients with waldenstr\u00f6m macroglobulinemia from the ASPEN study","volume":"9","author":"Garc\u00eda-Sanz","year":"2025","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S250823","article-title":"Zanubrutinib (BGB-3111), a second-generation selective covalent inhibitor of bruton\u2019s tyrosine kinase and its utility in treating chronic lymphocytic leukemia","volume":"15","author":"Rhodes","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.013","article-title":"A systematic review of paraneoplastic pemphigus and paraneoplastic autoimmune multiorgan syndrome: clinical features and prognostic factors","volume":"92","author":"Zou","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18931","article-title":"S2k guidelines on the management of paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome initiated by the European academy of dermatology and venereology (EADV)","volume":"37","author":"Antiga","year":"2023","journal-title":"J Eur Acad Dermatol Venereol Jeadv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81033","article-title":"Complete resolution of atypical paraneoplastic pemphigus following treatment with dupilumab","volume":"17","author":"Pinero-Crespo","year":"2025","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.043","article-title":"Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults","volume":"80","author":"Ouedraogo","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncolj Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/all.15261","article-title":"Bruton\u2019s tyrosine kinase inhibition-an emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"77","author":"Mendes-Bastos","year":"2022","journal-title":"Allergy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14004","article-title":"Paraneoplastic pemphigus: revised diagnostic criteria based on literature analysis","volume":"48","author":"Svoboda","year":"2021","journal-title":"J Cutan Pathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1876086\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:36:40Z","timestamp":1789450600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1876086\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1876086"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1876086","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1876086"}}